HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ultragen’s Stop device

This article was originally published in The Rose Sheet

Executive Summary

Ultragen is launching skin-renewal device Stop in France after partnering with French equipment supplier Logicom, according to Sept. 2 release. Hand-held Stop device offers consumers the opportunity to enjoy at home the aesthetic benefits of focused TriPollar radiofrequency originally developed for use exclusively in professional settings. According to Dr. Zion Azar, founder of Ultragen and creator of TriPollar, "Logicom has already secured a seven-figure order for the Stop, and we look forward to developing business in [France] further." Logicom will be responsible for overseeing retail partners and building long-term business relationships, Ultragen notes. Stop device, touted as an alternative to invasive surgical techniques for skin tightening, firming and renewal, is slated to launch in upscale UK department stores later this year (1"The Rose Sheet," Sept. 1, 2008, p. 9)

You may also be interested in...

Consumers Seeking RF Skin Renewal Can Stop Going To Clinic, Stay At Home

Ultragen Ltd. enters the growing market for home-use aesthetic devices with its hand-held Stop skin renewal device, which uses TriPollar radiofrequency technology to reduce visible signs of aging, the company says

Strides Targets $200-400m From Generic Injectables In Mid-Term

Strides has set a sales target of $200-400m for Stelis’s generic injectables business in two to four years as part of its plan to reach $800m in total revenues in four years. Meanwhile, Stelis’s Rh-teriparatide for osteoporosis and sodium hyaluronate for osteoarthritis await Phase III incremental studies in the US.

Abbott Readying Vildagliptin ER In India Amid Price Competition

Abbott is developing an extended release version of vildagliptin in India, adding a new dimension to the market dynamics for the DPP-4 inhibitor, which has seen a key patent expire. Sustained release vildagliptin products from Wockhardt and Synokem also appear to be in the works.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts